Baxter International has climbed back into positive territory over the last year, yet the stock still carries a long 5 year track record of losses. Investors are asking whether the recent rebound and fresh optimism around the business are now fully reflected in the share price, or if there is still a margin between market price and intrinsic value based on a Discounted Cash Flow (DCF) view.

• Over the last 5 years Baxter International has declined 59.1%, which means the stock is coming into this recovery from a deep drawdown.
• The recent share reaction to stronger revenue trends can support higher valuation expectations, while the decision to launch up to US$500m of cash tender offers for notes highlights ongoing balance sheet and funding trade offs that may still weigh on how investors price risk.
• On Simply Wall St's broader checks, Baxter International screens as undervalued in 5 of 6 valuation tests. This points to a company that the model suggests is cheap on several measures even after the recent rally 5.

The issue now is whether a DCF based intrinsic value estimate that sits about 25.5% above the current market price is enough to compensate for Baxter International's mixed long term share performance.

Is Baxter International Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here uses projected free cash flows to estimate what Baxter International might be worth today. On this view, the latest twelve month free cash flow sits at about $850.3 million, with the model assuming growing cash flows rather than a sharp step change or decline. That stream of cash, discounted back, leads to an estimated intrinsic value of about $36.68 per share.

Compared with the current market price, this implies Baxter International trades at roughly a 25.5% discount, based on this cash flow outlook. Baxter’s recent Q2 revenue update and raised 2026 sales growth outlook may help explain why the market has repriced the stock, yet the DCF still points to more value than the share price reflects.

On this DCF view, Baxter International stock currently appears undervalued relative to the cash flows the business is expected to generate.

Our Discounted Cash Flow (DCF) analysis suggests Baxter International is undervalued by 25.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Is Baxter International Fairly Priced on Sales?

P/S is often useful for Baxter International because revenue is a cleaner yardstick for a medical equipment business than earnings, which can be skewed by one off items and heavy investment.

Baxter International currently trades on a P/S of about 1.2x, which sits below both the wider medical equipment industry average of 2.9x and the peer group average of 4.4x. The fair P/S ratio suggested by the model is around 1.3x, only slightly above the current level. That gap is small, which points to a market price that is broadly in line with what the company’s revenue base and risk profile might support on this framework.

For investors weighing the DCF indication against this sales multiple view, the P/S check suggests that Baxter International’s recent share price move has brought it close to what the model views as a reasonable range on revenue.

On the P/S yardstick, Baxter International now appears roughly fairly valued relative to what the model considers a reasonable sales multiple.

The Baxter International Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the valuation checks leave off for Baxter International by spelling out which paths for growth, margins and earnings would make the stock worth materially more or less than today’s price on the Community page. Each narrative ties its numbers to a clear view on how Baxter International's growth, profitability and risks could evolve, giving you a reference point you can revisit as fresh information comes through.

The community is split on Baxter International, with one camp seeing room for repricing and another warning that expectations already look stretched.

Bull case: 20% undervalued

"Baxter's streamlined post-divestiture structure, coupled with the incoming CEO's aggressive operational track record and focus on innovation, sets the company up for transformation, unlocking cost reductions and margin expansion beyond current expectations as new leadership re-aligns resources for high-growth areas…"

Bear case: 61% overvalued

"Accelerating adoption of preventive care and at-home digital health solutions is reducing demand for traditional hospital-based therapies, which underpin a major share of Baxter's product portfolio; this sustained shift will erode the addressable market for Baxter's IV solutions, infusion pumps and hospital-focused therapies, undermining both top-line revenue and earnings growth…"

Do you think there's more to the story for Baxter International? Head over to our Community to see what others are saying!

The Bottom Line

Baxter International screens as undervalued on the Discounted Cash Flow (DCF) view, yet the revenue based multiple suggests the current share price is now close to what peers might justify. The broader checks still lean in favor of value, although not in an extreme way. This leaves less obvious upside after the recent rerating. From here, the key question is whether Baxter International can translate its current cash flow outlook into sustained execution without balance sheet or demand risks turning that apparent discount into a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.